RUTI: A new chance to shorten the treatment of latent tuberculosis infection

Tuberculosis

Volumn 86, Issue 3-4 SPEC. ISS., 2006, Pages 273-289

  Cardona, Pere Joan ^a  

^a FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Chemotherapy; Foamy macrophages; Immunotherapy; Latent tuberculosis infection; Mycobacterium tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BACTERIAL VACCINE; BCG VACCINE; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; ISONIAZID; LIPOSOME; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; RIFAMPICIN; ROFECOXIB;

ANTIGENICITY; ARTICLE; CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; GRANULOMA; GUINEA PIG; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INOCULATION; LUNG ALVEOLUS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TH3 CELL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; GRANULOMA; GUINEA PIGS; HUMANS; MACROPHAGES; MICE; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 33646473076     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2006.01.024     Document Type: Article

References (129)

1. Wayne L.G., and Sramek H.A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 38 (1994) 2054-2058
2. Wayne L.G., and Sohaskey C.D. Nonreplicating persistence of mycobacterium tuberculosis. Annu Rev Microbiol 55 (2001) 139-163
3. Wayne L.G., and Lin K.Y. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 37 (1982) 1042-1049
4. Mochizuki M. Kinetics of oxygen and carbon dioxide reactions. In: Crystal R.G., West J.B., et al. (Eds). The lung: scientific foundations vol. 5.3.2.4 (1991), Raven Press Ltd, New York 1241-1252
5. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., and Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 178 (1993) 2243-2247
6. Gil O, Guirado E, Gordillo S, et al. Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type. Micr Infect. Available online 17 January 2006.
7. McCune R.M., Feldmann F.M., Lambert H.P., and McDermott W. Microbial persistence I The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 123 (1966) 445-468
8. American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161 (2000) S221-S247
9. Lucas S.B. Histopathology. In: Davies P.D.O. (Ed). Clinical tuberculosis vol. 8 (1998), Chapman & Hall, London 113-127
10. In: Gomez J.E., and McKinney J.D. (Eds). M. tuberculosis persistence latency and drug tolerance. Tuberculosis (Edinburgh) 84 (2004) 29-44
11. Orme I.M. The latent tuberculosis bacillus I'll let you know if I ever meet one. Int J Tuberc Lung Dis 5 (2001) 589-593
12. Wallis R.S., Patil S., Cheon S.H., et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43 (1999) 2600-2606
13. Shleeva M.O., Bagramyan K., Telkov M.V., et al. Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology 148 (2002) 1581-1591
14. Kell D.B., and Young M. Bacterial dormancy and culturability: the role of autocrine growth factors. Curr Opin Microbiol 3 (2000) 238-243
15. Wallace J.G. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Rev Respir Dis 83 (1961) 866-871
16. Muñoz-Elias E.J., Timm J., Botha T., Chan W.T., Gomez J.E., and McKinney J.D. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun 73 (2005) 546-551
17. Lazarevic V., Nolt D., and Flynn J.L. Long-term control of Mycobacterium tuberculosis infection is mediated by dynamic immune responses. J Immunol 175 (2005) 1107-1117
18. Thoen C.O. Tuberculosis in wild and domestic mammals. In: Bloom B.R. (Ed). Tuberculosis pathogenesis protectiction and control vol. 11 (1994), ASM Press, Washington, DC 157-164
19. Rook G.A., and Attiyah R. Cytokines and the Koch phenomenon. Tubercle 72 (1991) 13-20
20. Cardona P.J., Llatjos R., Gordillo S., et al. Towards a 'human-like' model of tuberculosis: intranasal inoculation of LPS induces intragranulomatous lung necrosis in mice infected aerogenically with Mycobacterium tuberculosis. Scand J Immunol 53 (2001) 65-71
21. Ryll R., Kumazawa Y., and Yano I. Immunological properties of trehalose dimycolate cord factor and other mycolic acid-containing glycolipids-a review. Microbiol Immunol 45 (2001) 801-811
22. Indrigo J., Hunter Jr. R.L., and Actor J.K. Cord factor trehalose 66'-dimycolate TDM mediates trafficking events during mycobacterial infection of murine macrophages. Microbiology 149 (2003) 2049-2059
23. Flynn J.L., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 9 (2001) 93-129
24. In: Orme I.M. (Ed). The mouse as a useful model of tuberculosis. Tuberculosis (Edinburgh) 83 (2003) 112-115
25. North R.J., and Jung Y.J. Immunity to tuberculosis. Annu Rev Immunol 22 (2004) 599-623
26. Cardona P.J., Llatjos R., Gordillo S., et al. Evolution of granulomas in lungs of mice infected aerogenically with Mycobacterium tuberculosis. Scand J Immunol 52 (2000) 156-163
27. Cardona P.J., Gordillo S., Diaz J., et al. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect Immun 71 (2003) 5845-5854
28. Green G.M., and Burlington V.T. Alveolobronchiolar transport mechanisms. Arch Intern Med 131 (1973) 109-114
29. Korf J., Stoltz A., Verschoor J., De Baetselier P., and Grooten J. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur J Immunol 35 (2005) 890-900
30. Eriksson U., Egermann U., Bihl M.P., et al. Human bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. J Immunol 175 (2005) 2715-2720
31. Mills C.D. Molecular basis of "suppressor" macrophages Arginine metabolism via the nitric oxide synthetase pathway. J Immunol 46 (1991) 2719-2723
32. Bingisser R.M., Tilbrook P.A., Holt P.G., and Kees U.R. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160 (1998) 5729-5734
33. Nabeshima S., Nomoto M., Matsuzaki G., et al. T-Cell hyporesponsiveness induced by activated macrophages through nitric oxide production in mice infected with Mycobacterium tuberculosis. Infect Immun 67 (1999) 3221-3226
34. Chan E.D., Chan J., and Schluger N.W. What is the role of nitric oxide in murine and human host defense against tuberculosis? Current knowledge. Am J Respir Cell Mol Biol 25 (2001) 606-612
35. Flynn J.L., Scanga C.A., Tanaka K.E., and Chan J. Effects of aminoguanidine on latent murine tuberculosis. J Immunol 160 (1998) 1796-1803
36. Lamas S., Michel T., Brenner B.M., and Marsden P.A. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF-alpha. Am J Physiol 261 (1991) C634-C641
37. Nussler A.K., Di Silvio M., Billiar T.R., et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 176 (1992) 261-264
38. Chu S.C., Marks-Konczalik J., Wu H.P., Banks T.C., and Moss J. Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. Biochem Biophys Res Commun 248 (1998) 871-878
39. Kolb J.P., Paul-Eugene N., Damais C., Yamaoka K., Drapier J.C., and Dugas B. Interleukin-4 stimulates cGMP production by IFN-gamma-activated human monocytes. Involvement of the nitric oxide synthase pathway. J Biol Chem 269 (1994) 9811-9816
40. Guo F.H., Uetani K., Haque S.J., et al. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J Clin Invest 100 (1997) 829-838
41. Eigler A., Moeller J., and Endres S. Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. J Immunol 154 (1995) 4048-4054
42. Eriksson U., Egermann U., Bihl M.P., et al. Human bronchial epithelium controls TH2 responses by TH1-induced, nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. J Immunol 175 (2005) 2715-2720
43. Cooper A.M., Adams L.B., Dalton D.K., Appelberg R., and Ehlers S. IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol 10 (2002) 221-226
44. Hernandez-Pando R., Schon T., Orozco E.H., Serafin J., and Estrada-Garcia I. Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis. Exp Toxicol Pathol 53 (2001) 257-265
45. Yu K., Mitchell C., Xing Y., Magliozzo R.S., Bloom B.R., and Chan J. Toxicity of nitrogen oxides and related oxidants on mycobacteria: M. tuberculosis is resistant to peroxynitrite anion. Tuber Lung Dis 79 (1999) 191-198
46. Robinson V.K., Sato E., Nelson D.K., Camhi S.L., Robbins R.A., and Hoyt J.C. Peroxynitrite inhibits inducible (type 2) nitric oxide synthase in murine lung epithelial cells in vitro. Free Radic Biol Med 30 (2001) 986-991
47. Moriwaki H., Kume N., Kataoka H., et al. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. FEBS Lett 440 (1998) 29-32
48. Smirnova I.V., Kajstura M., Sawamura T., and Goligorsky M.S. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 287 (2004) H782-H790
49. Kruth H.S., Huang W., Ishii I., and Zhang W.Y. Macrophage foam cell formation with native low density lipoprotein. J Biol Chem 277 (2002) 34573-34580
50. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8 (2002) 1235-1242
51. Burleigh M.E., Babaev V.R., Oates J.A., et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105 (2002) 1816-1823
52. Wright J.R. Immunomodulatory functions of surfactant. Physiol Rev 77 (1997) 931-962
53. Lian X., Yan C., Yang L., Xu Y., and Du H. Lysosomal acid lipase deficiency causes respiratory inflammation and destruction in the lung. Am J Physiol Lung Cell Mol Physiol 286 (2004) L801-L807
54. Kramer B.W., Jobe A.H., and Ikegami M. Exogenous surfactant changes the phenotype of alveolar macrophages in mice. Am J Physiol Lung Cell Mol Physiol 280 (2001) L689-L694
55. Chan E.D., Morris K.R., Belisle J.T., et al. Induction of inducible nitric oxide synthase-NO* by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEK1-ERK, MKK7-JNK, and NF-kappaB signaling pathways. Infect Immun 69 (2001) 2001-2010
56. Rhoades E.R., and Orme I.M. Susceptibility of a panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect Immun 65 (1997) 1189-1195
57. Brugmann W.B., and Firmani M.A. Low concentrations of nitric oxide exert a hormetic effect on Mycobacterium tuberculosis in vitro. J Clin Microbiol 43 (2005) 4844-4846
58. Ciccone R., Mariani F., Cavone A., et al. Inhibitory effect of NO-releasing Ciprofloxacin (NCX 976) on Mycobacterium tuberculosis survival. Antimicrob Agents Chemother 43 (2003) 2299-2305
59. Voskuil M.I., Schnappinger D., Visconti K.C., et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198 (2003) 705-712
60. Schnappinger D., Ehrt S., Voskuil M.I., et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal environment. J Exp Med 198 (2003) 693-700
61. Ohno H., Zhu G., Mohan V.P., et al. The effects of reactive nitrogen intermediates on gene expression in Mycobacterium tuberculosis. Cell Microbiol 5 (2003) 637-645
62. Darwin K.H., Ehrt S., Gutierrez-Ramos J.C., Weich N., and Nathan C.F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302 (2003) 1963-1969
63. Hernandez-Pando R., Orozco H., Arriaga K., Sampieri A., Larriva-Sahd J., and Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha tumour necrosis factor-alpha and transforming growth factor-beta during the course of experimental pulmonary tuberculosis. Immunology 90 (1997) 607-617
64. Ordway D., Henao-Tamayo M., Orme I.M., and Gonzalez-Juarrero M. Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. J Immunol 175 (2005) 3873-3881
65. Cardona P.J., Julian E., Valles X., et al. Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis. Scand J Immunol 55 (2002) 639-645
66. Shalit I., Horev-Azaria L., Fabian I., et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother 46 (2002) 2442-2449
67. Werber S., Shalit I., Fabian I., Steuer G., Weiss T., and Blau H. Moxifloxacin inhibits cytokine-induced MAP kinase and NF-kappaB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. J Antimicrob Chemother 55 (2005) 293-300
68. Dunn P.L., and North R.J. Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs induce lung pathology and cause mortality in mice. Infect Immun 63 (1995) 3428-3437
69. Grode L., Seiler P., Baumann S., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115 (2005) 2472-2479
70. Ramachandra L., Noss E., Boom W.H., and Harding C.V. Processing of Mycobacterium tuberculosis antigen 85B involves intraphagosomal formation of peptide-major histocompatibility complex II complexes and is inhibited by live bacilli that decrease phagosome maturation. J Exp Med 194 (2001) 1421-1432
71. Ramachandra L., Smialek J.L., Shank S.S., Convery M., Boom W.H., and Harding C.V. Phagosomal processing of Mycobacterium tuberculosis antigen 85B is modulated independently of mycobacterial viability and phagosome maturation. Infect Immun 73 (2005) 1097-1105
72. Schaible U.E., Winau F., Sieling P.A., et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9 (2003) 1039-1046
73. Turner O.C., Basaraba R.J., and Orme I.M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 71 (2003) 864-871
74. Ulrichs T., Kosmiadi G.A., Jorg S., et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J Infect Dis 192 (2005) 89-97
75. Fisher M.A., Plikaytis B.B., and Shinnick T.M. Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol 184 (2002) 4025-4032
76. Colston M.J., and Cox R.A. Mycobacterial growth and dormancy. In: Ratledge C., and Dale J. (Eds). Mycobacteria molecular biology and virulence vol. 11 (1999), Blackwell Science, London 198-219
77. Cardona P.J., and Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J 24 (2004) 1044-1051
78. Rook G.A., Hernandez-Pando R., Dheda K., and Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25 (2004) 483-488
79. Dheda K., Booth H., Huggett J.F., Johnson M.A., Zumla A., and Rook G.A. Lung Remodeling in Pulmonary Tuberculosis. J Infect Dis 192 (2005) 1201-1209
80. Aung H., Toossi Z., McKenna S.M., et al. Expression of transforming growth factor-beta but not tumor necrosis factor-alfa interferon-gamma and interleukin-4 in granulomatous lung lesions in tuberculosis. Tubercle Lung Dis 80 (2000) 61-67
81. Fenhals G., Wong A., Bezuidenhout J., van Helden P., Bardin P., and Lukey P.T. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun 68 (2000) 2827-2836
82. Comstock G.W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 3 (1999) 847-850
83. Jindani A., Dore C.J., and Mitchison D.A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167 (2003) 1348-1354
84. Mitchison D.A. Basic mechanisms of chemotherapy. Chest 76 (1979) 771-781
85. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1 (1980) 231-241
86. Olsen A.W., Brandt L., Agger E.M., van Pinxteren L.A., and Andersen P. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand J Immunol 60 (2004) 273-277
87. Cardona P.J., Amat I., Gordillo S., et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23 (2005) 1393-1398
88. Orme I.M., Andersen P., and Boom W.H. T cell response to Mycobacterium tuberculosis. J Infect Dis 167 (1993) 1481-1497
89. Peters A.C., Wimpenny J.W., and Coombs J.P. Oxygen profiles in and in the agar beneath colonies of Bacillus cereus Staphylococcus albus and Escherichia coli. J Gen Microbiol 133 (1987) 1257-1263
90. Robinson T.P., Wimpenny J.W., and Earnshaw R.G. pH gradients through colonies of Bacillus cereus and the surrounding agar. J Gen Microbiol 137 (1991) 2885-2889
91. Leserman L. Liposomes as protein carriers in immunology. J Liposome Res 14 (2004) 175-189
92. Larson C.L., Bell J.F., List R.H., Ribi E., and Wicht W.C. Symposium on relationship of structure of microorganisms to their immunological properties II host-reactive properties of cell walls and protoplasm from mycobacteria. Bacteriol Rev 27 (1963) 341-351
93. Dannenberg Jr. A.M. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology 191 (1994) 461-473
94. Moreira A.L., Tsenova L., Aman M.H., et al. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 70 (2002) 2100-2107
95. Taylor J.L., Ordway D.J., Troudt J., Gonzalez-Juarrero M., Basaraba R.J., and Orme I.M. Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA. Infect Immun 73 (2005) 5189-5193
96. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 2003;83:91-7.
97. Gil O, Guirado E, Amat I, et al. The control of latent tuberculosis infection after a short-course chemotherapy induced by RUTI is related to the increase of PPD-specific CD8+ cells in the lungs and the reduction of pulmonary dissemination through a policlonal humoral response New approaches to vaccine development, Berlin, September 2005.
98. Turner J., Rhoades E.R., Keen M., Belisle J.T., Frank A.A., and Orme I.M. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 68 (2000) 1706-1709
99. van Pinxteren L.A., Cassidy J.P., Smedegaard B.H., Agger E.M., and Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30 (2000) 3689-3698
100. Agger E.M., and Andersen P. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine 21 (2002) 7-14
101. Soruri A., Schweyer S., Radzun H.J., and Fayyazi A. Mycobacterial antigens induce apoptosis in human purified protein derivative-specific alphabeta T lymphocytes in a concentration-dependent manner. Immunology 105 (2002) 222-230
102. Schaible U.E., Winau F., Sieling P.A., Fischer K., Collins H.L., Hagens K., Modlin R.L., Brinkmann V., and Kaufmann S.H. Apoptosis facilitates antigen presentation to Tlymphocytes through MHC-1 and CDI in tuberculosis. Nat Med 9 (2003) 1039-1046
103. Guirado E, Amat I, Gil O, et al. Passive serum-therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microb Infect. Available online 27 January 2006.
104. Glatman-Freedman A. Advances in antibody-mediated immunity against Mycobacterium tuberculosis: implications for a novel vaccine strategy. FEMS Immunol Med Microbiol 39 (2003) 9-16
105. Williams A., Reljic R., Naylor I., et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 111 (2004) 328-333
106. Roy E., Stavropoulos E., Brennan J., et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 73 (2005) 6101-6109
107. Costello A.M., Kumar A., Narayan V., et al. Does antibody to mycobacterial antigens including lipoarabinomannan limit dissemination in childhood tuberculosis?. Trans R Soc Trop Med Hyg 86 (1992) 686-692
108. Sanchez-Rodriguez C., Estrada-Chavez C., Garcia-Vigil J., et al. An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis. Int J Tuberc Lung Dis 6 (2002) 706-712
109. Langermans J.A., Andersen P., van Soolingen D., et al. Divergent effect of bacillus Calmette-Guerin BCG vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 98 (2001) 11497-11502
110. Sime P.J., Xing Z., Graham F.L., Csaky K.G., and Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100 (1997) 768-776
111. Demissie A., Abebe M., Aseffa A., et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol 172 (2004) 6938-6943
112. Malhotra I., Mungai P., Wamachi A., et al. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 162 (1999) 6843-6848
113. Prescott S.L., Macaubas C., Holt B.J., et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J Immunol 160 (1998) 4730-4737
114. In: Gruppo V., and Orme I.M. (Eds). Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 82 (2002) 267-273
115. Jung Y.J., LaCourse R., Ryan L., and North R.J. Evidence inconsistent with a negative influence of T helper 2 cells on protection afforded by a dominant T helper 1 response against Mycobacterium tuberculosis lung infection in mice. Infect Immun 70 (2002) 6436-6443
116. Jung Y.J., Ryan L., LaCourse R., and North R.J. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice. Immunology 109 (2003) 295-299
117. Turner J., Frank A.A., Brooks J.V., Gonzalez-Juarrero M., and Orme I.M. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. Exp Gerontol 36 (2001) 537-545
118. Lowrie D.B., Tascon R.E., Bonato V.L., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400 (1999) 269-271
119. Nuermberger E, Tyagi S, Williams KN, Rosenthal I, Bishai WR, Grosset JH. Rifapentine Moxifloxacin or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am J Respir Crit Care Med 2005.
120. Van Eden W., Van Der Zee R., Van Kooten P., et al. Balancing the immune system: Th1 and Th2. Ann Rheum Dis 61 Suppl 2 (2002) ii25-ii28
121. Silva C.L., Bonato V.L., Coelho-Castelo A.A., et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther 12 (2005) 281-287
122. Rook G.A., Dheda K., and Zumla A. Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?. Vaccine 23 (2005) 2115-2120
123. Wilkinson K, Kon OM, Newton S, et al. T cell monitoring of treatment for latent tuberculosis infection. In: Sixth international conference on the pathogenesis of mycobacterial infections. Stockholm. Sweden: Saltsjöbaden; June 2005
124. Orme I.M., McMurray D.N., and Belisle J.T. Tuberculosis vaccine development: recent progress. Trends Microbiol 9 (2001) 115-118
125. Lecoeur H.F., Truffot-Pernot C., and Grosset J.H. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140 (1989) 1189-1193
126. Cardona PJ, Amat I, Gordillo S, et al. El tratamiento inmunoterápico con RUTI de la infección experimental por Mycobacterium tuberculosis también es eficaz en huéspedes resistentes a la infección. Abstract XI. Congreso Sociedad Española de Enfermedades Infecciósa y Microbiología Clínica. Bilbao, Euzkadi, Spain. June 2003.
127. Guirado E, Gil O, Díaz J, et al. Immunotherapy with RUTI is useful in the treatment of latent infection in the experimental model of tuberculosis in guinea pigs. In: Sixth international conference on the pathogenesis of mycobacterial infections. Stockholm. Sweden: Saltsjöbaden; June 2005
128. Middlebrook G. Immunological aspects of airborne infection: reactions to inhaled antigens. Bacteriol Rev 25 (1961) 331-346
129. Ferebee S.H. Controlled chemoprophylaxis trials in tuberculosis A general review. Adv Tuberc Res 17 (1970) 28-106